Wird geladen...
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model
The AKT/mammalian target of rapamycin (AKT/mTOR) and ERK MAPK signaling pathways have been shown to cooperate in prostate cancer progression and the transition to androgen-independent disease. We have now tested the effects of combinatorial inhibition of these pathways on prostate tumorigenicity by...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , , |
---|---|
Format: | Artigo |
Sprache: | Inglês |
Veröffentlicht: |
American Society for Clinical Investigation
2008
|
Schlagworte: | |
Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2518074/ https://ncbi.nlm.nih.gov/pubmed/18725989 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI34764 |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|